Heat Biologics, Inc.
Heat Biologics is developing its proprietary "ImPACT" (Immune Pan-Antigen Cytotoxic Therapy) off-the-shelf therapeutic vaccines for oncology and antiviral applications. ImPACT uses engineered cancer cell lines to produce an immuno-stimulatory protein called gp96-Ig along with chaperoned cellular antigens to stimulate the immune system to issue a pan-antigen cytotoxic attack against cancer or virus-infected cells. The company's lead program is entering Phase 2 clinical trials against non-small cell lung cancer in October. Heat also has bladder cancer and ovarian cancer programs planned to begin clinical trials in early 2012 and a grant-funded HIV program in advanced primate studies.